Department of Bacteriology and Immunology, Beijing Key Laboratory on Drug-Resistant Tuberculosis Research, Beijing Tuberculosis and Thoracic Tumor Research Institute/Beijing Chest Hospital, Capital Medical University, Beijing, People's Republic of China.
Innovation Alliance on Tuberculosis Diagnosis and Treatment, Beijing, People's Republic of China.
Int J Infect Dis. 2022 Aug;121:148-151. doi: 10.1016/j.ijid.2022.05.030. Epub 2022 May 13.
We aimed to determine the breakpoint of cycloserine (CS) susceptibility in MGIT and to describe the molecular characteristics of CS-resistant Mycobacterium tuberculosis (MTB) isolates.
A total of 124 MTB isolates were recruited in our analysis. Minimum inhibitory concentration (MIC) was determined using the MGIT system. The mutations of MTB isolates within alr, ddl, ald, and cycA, potentially conferring CS resistance were analyzed by the whole-genome sequencing.
In vitro drug susceptibility testing of isolates with doubling concentrations of CS revealed that the modal MIC values was 4 mg/L for MGIT, accounting for 35.5% (44/124) of isolates tested. Seven isolates harbored mutations conferring CS resistance, consisting of five with alr mutations and two with ald mutations. On the basis of the MIC distributions of wild-type and resistotype populations, we proposed a tentative epidemiologic cut-off value of 16 mg/l. The proportion of CS resistance in extensively drug-resistant TB was significantly higher than that of multidrug-resistant TB.
In conclusion, we propose critical concentration for MGIT 960 to properly diagnose CS-resistant MTB and demonstrate that mutations in alr and ald genes are the major mechanism conferring CS resistance in clinical isolates.
我们旨在确定环丝氨酸(CS)在 MGIT 中的药敏断点,并描述 CS 耐药结核分枝杆菌(MTB)分离株的分子特征。
我们对 124 株 MTB 分离株进行了分析。采用 MGIT 系统测定最小抑菌浓度(MIC)。通过全基因组测序分析可能导致 CS 耐药的 MTB 分离株中 alr、ddl、ald 和 cycA 内的突变。
对 CS 浓度加倍的分离株进行的体外药敏试验显示,MGIT 的模式 MIC 值为 4 mg/L,占检测的 124 株分离株的 35.5%(44/124)。有 7 株分离株携带有 CS 耐药相关的突变,其中 5 株具有 alr 突变,2 株具有 ald 突变。根据野生型和耐药型群体的 MIC 分布,我们提出了一个暂定的流行病学截断值为 16 mg/L。在广泛耐药结核病中的 CS 耐药比例明显高于耐多药结核病。
综上所述,我们提出了 MGIT 960 的临界浓度,以正确诊断 CS 耐药 MTB,并证实 alr 和 ald 基因突变是临床分离株中 CS 耐药的主要机制。